grant
Immunologic Monitoring (IM)
Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 1 Jun 1997Deadline 31 May 2028
NIHUS FederalResearch GrantFY2025Antineoplastic VaccineAssayBasic ResearchBasic ScienceBioassayBiologic ModelsBiological AssayBiological ModelsCCSGCancer CenterCancer Center Support GrantCancer TreatmentCancer VaccinesCancersClinical ResearchClinical SciencesClinical StudyCytometryDataDevelopmentELISAEnsureEnzyme-Linked Immunosorbent AssayEquipmentFosteringFundingFutureGoalsGvHDHealth Services EvaluationHealth Services ResearchHomologous Wasting DiseaseImageImmuneImmune Modulation TherapyImmune MonitoringImmune mediated therapyImmune responseImmunesImmunologic MonitoringImmunological MonitoringImmunologically Directed TherapyImmunomonitoringImmunotherapyInflammatory ResponseInnate ImmunityInvestigationInvestigatorsKnowledgeLaboratoriesLeadershipMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMedical Care ResearchMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMichiganMicrobeModel SystemMonitorNative ImmunityNatural ImmunityNatureNeoplasm MetastasisNeoplasm VaccinesNon-Specific ImmunityNonspecific ImmunityOncogenicPathway interactionsPatientsPopulation SciencesProceduresPublicationsQuality ControlRegulationResearchResearch PersonnelResearch SupportResearchersResource SharingRoleRunt DiseaseSamplingScientific PublicationSecondary NeoplasmSecondary TumorServicesStaining methodStainsStandardizationSuspension substanceSuspensionsTechnologyTranslational ResearchTranslational ScienceTreatment EfficacyTumor VaccinesUniversitiesadaptive immunityanti-cancer therapyanti-tumor vaccinecancer initiationcancer metastasiscancer microenvironmentcancer therapycancer-directed therapycost effectivecost efficientcytokinedevelopmentalenzyme linked immunoassaygraft versus host diseasegraft vs host diseasegraft vs. host diseasehost responseimagingimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmuno therapyimmunogenicimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory biologicsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulatory therapyimmunoregulatory treatmentimmunoresponseintervention efficacymalignancymemberneoplasm/cancerpathwayprogramsresistance to therapyresistant to therapyservices researchsocial roletherapeutic efficacytherapeutic immunomodulationtherapeutic immunoregulationtherapeutic resistancetherapy efficacytherapy resistanttranslation researchtranslational investigationtreatment resistancetumor cell metastasistumor microenvironmentvaccine for cancer
Description preview
The Immune Monitoring Shared Resource (IM-SR) was established by the University of Michigan (U-M) Rogel
Cancer Center (Rogel) in 1999 and has been continuously funded by the Cancer Center Support Grant
(CCSG) since 2001. The goal of IM-SR is to foster, facilitate, and support basic, translational, clinical, and
population science researchers…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click